These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36493840)

  • 1. Rationale and design of the Effects of intensive Systolic blood Pressure lowering treatment in reducing RIsk of vascular evenTs (ESPRIT): A multicenter open-label randomized controlled trial.
    Liu J; Wang B; Li Y; Yan X; Ge J; Li J
    Am Heart J; 2023 Mar; 257():93-102. PubMed ID: 36493840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).
    Ambrosius WT; Sink KM; Foy CG; Berlowitz DR; Cheung AK; Cushman WC; Fine LJ; Goff DC; Johnson KC; Killeen AA; Lewis CE; Oparil S; Reboussin DM; Rocco MV; Snyder JK; Williamson JD; Wright JT; Whelton PK;
    Clin Trials; 2014 Oct; 11(5):532-46. PubMed ID: 24902920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
    Blood Pressure Lowering Treatment Trialists' Collaboration
    Lancet; 2021 May; 397(10285):1625-1636. PubMed ID: 33933205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).
    Soliman EZ; Ambrosius WT; Cushman WC; Zhang ZM; Bates JT; Neyra JA; Carson TY; Tamariz L; Ghazi L; Cho ME; Shapiro BP; He J; Fine LJ; Lewis CE;
    Circulation; 2017 Aug; 136(5):440-450. PubMed ID: 28512184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal blood pressure targets for patients with hypertension: a systematic review and meta-analysis.
    Sakima A; Satonaka H; Nishida N; Yatsu K; Arima H
    Hypertens Res; 2019 Apr; 42(4):483-495. PubMed ID: 30948822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
    Blood Pressure Lowering Treatment Trialists' Collaboration
    Lancet; 2021 Sep; 398(10305):1053-1064. PubMed ID: 34461040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Acute Kidney Injury with Cardiovascular Events and Death in Systolic Blood Pressure Intervention Trial.
    Dieter BP; Daratha KB; McPherson SM; Short R; Alicic RZ; Tuttle KR
    Am J Nephrol; 2019; 49(5):359-367. PubMed ID: 30939480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis.
    Pinho-Gomes AC; Azevedo L; Copland E; Canoy D; Nazarzadeh M; Ramakrishnan R; Berge E; Sundström J; Kotecha D; Woodward M; Teo K; Davis BR; Chalmers J; Pepine CJ; Rahimi K;
    PLoS Med; 2021 Jun; 18(6):e1003599. PubMed ID: 34061831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension.
    Zhang W; Zhang S; Deng Y; Wu S; Ren J; Sun G; Yang J; Jiang Y; Xu X; Wang TD; Chen Y; Li Y; Yao L; Li D; Wang L; Shen X; Yin X; Liu W; Zhou X; Zhu B; Guo Z; Liu H; Chen X; Feng Y; Tian G; Gao X; Kario K; Cai J;
    N Engl J Med; 2021 Sep; 385(14):1268-1279. PubMed ID: 34491661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.
    Xie X; Atkins E; Lv J; Bennett A; Neal B; Ninomiya T; Woodward M; MacMahon S; Turnbull F; Hillis GS; Chalmers J; Mant J; Salam A; Rahimi K; Perkovic V; Rodgers A
    Lancet; 2016 Jan; 387(10017):435-43. PubMed ID: 26559744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Böhm M; Schumacher H; Teo KK; Lonn E; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder R; Weber M; Sliwa K; Williams B; Yusuf S
    Eur Heart J; 2018 Sep; 39(33):3105-3114. PubMed ID: 29873709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Optimal Diastolic Blood Pressure Range Among Adults With Treated Systolic Blood Pressure Less Than 130 mm Hg.
    Li J; Somers VK; Gao X; Chen Z; Ju J; Lin Q; Mohamed EA; Karim S; Xu H; Zhang L
    JAMA Netw Open; 2021 Feb; 4(2):e2037554. PubMed ID: 33595663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial.
    Bangalore S; Fayyad R; Messerli FH; Laskey R; DeMicco DA; Kastelein JJ; Waters DD
    Am J Cardiol; 2017 Feb; 119(3):379-387. PubMed ID: 27939230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial.
    Mazighi M; Richard S; Lapergue B; Sibon I; Gory B; Berge J; Consoli A; Labreuche J; Olivot JM; Broderick J; Duhamel A; Touze E; Qureshi AI; Yavchitz A; Escalard S; Desilles JP; Redjem H; Smajda S; Fahed R; Hébert S; Maïer B; Delvoye F; Boursin P; Maacha MB; Obadia M; Sabben C; Blanc R; Savatovsky J; Piotin M;
    Lancet Neurol; 2021 Apr; 20(4):265-274. PubMed ID: 33647246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal.
    Zanchetti A; Thomopoulos C; Parati G
    Circ Res; 2015 Mar; 116(6):1058-73. PubMed ID: 25767290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Intensive Blood Pressure Lowering on Cardiovascular Outcomes: A Systematic Review Prepared for the 2020 U.S. Department of Veterans Affairs/U.S. Department of Defense Guidelines.
    D'Anci KE; Tipton K; Hedden-Gross A; Rouse B; Hermanson L; Fontanarosa J
    Ann Intern Med; 2020 Dec; 173(11):895-903. PubMed ID: 32866419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.
    Nazarzadeh M; Bidel Z; Canoy D; Copland E; Bennett DA; Dehghan A; Davey Smith G; Holman RR; Woodward M; Gupta A; Adler AI; Wamil M; Sattar N; Cushman WC; McManus RJ; Teo K; Davis BR; Chalmers J; Pepine CJ; Rahimi K;
    Lancet Diabetes Endocrinol; 2022 Sep; 10(9):645-654. PubMed ID: 35878651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial.
    He J; Ouyang N; Guo X; Sun G; Li Z; Mu J; Wang DW; Qiao L; Xing L; Ren G; Zhao C; Yang R; Yuan Z; Wang C; Shi C; Liu S; Miao W; Li G; Chen CS; Sun Y;
    Lancet; 2023 Mar; 401(10380):928-938. PubMed ID: 36871573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.
    Williamson JD; Supiano MA; Applegate WB; Berlowitz DR; Campbell RC; Chertow GM; Fine LJ; Haley WE; Hawfield AT; Ix JH; Kitzman DW; Kostis JB; Krousel-Wood MA; Launer LJ; Oparil S; Rodriguez CJ; Roumie CL; Shorr RI; Sink KM; Wadley VG; Whelton PK; Whittle J; Woolard NF; Wright JT; Pajewski NM;
    JAMA; 2016 Jun; 315(24):2673-82. PubMed ID: 27195814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics.
    Lonn E; Bosch J; Pogue J; Avezum A; Chazova I; Dans A; Diaz R; Fodor GJ; Held C; Jansky P; Keltai M; Keltai K; Kunti K; Kim JH; Leiter L; Lewis B; Liu L; Lopez-Jaramillo P; Pais P; Parkhomenko A; Peters RJ; Piegas LS; Reid CM; Sliwa K; Toff WD; Varigos J; Xavier D; Yusoff K; Zhu J; Dagenais G; Yusuf S;
    Can J Cardiol; 2016 Mar; 32(3):311-8. PubMed ID: 26481083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.